Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Davies

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
BMC Neurology|June 3, 2014
One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosisPeter W Thomas, Sarah Thomas, Paula Kersten, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2016
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium studySteven J Cohen, Bert H O'Neil, Jordan Berlin, et al.
Frontiers in Neurology|April 25, 2024
People with newly diagnosed multiple sclerosis benefit from a complex preventative intervention-a single group prospective study with follow upNatália Hrušková, Kateřina Berchová Bímová, Angela Davies Smith, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2013
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosisSarah Thomas, Peter W Thomas, Paula Kersten, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 24, 2012
The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. 1993David Vetrie, Igor Vořechovský, Paschalis Sideras, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
BMJ Open|August 23, 2023
Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessmentSally-Anne Dews, Adit Bassi, Sean Buckland, et al.
JMIR Formative Research|May 24, 2019
Digitizing a Face-to-Face Group Fatigue Management Program: Exploring the Views of People With Multiple Sclerosis and Health Care Professionals Via Consultation Groups and InterviewsSarah Thomas, Andy Pulman, Peter Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trialBarbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2004
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in CaliforniaCynthia L Martel, Yueju Li, Laurel Beckett, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
BMC Neurology|June 3, 2014
One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosisPeter W Thomas, Sarah Thomas, Paula Kersten, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2016
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium studySteven J Cohen, Bert H O'Neil, Jordan Berlin, et al.
Frontiers in Neurology|April 25, 2024
People with newly diagnosed multiple sclerosis benefit from a complex preventative intervention-a single group prospective study with follow upNatália Hrušková, Kateřina Berchová Bímová, Angela Davies Smith, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2013
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosisSarah Thomas, Peter W Thomas, Paula Kersten, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 24, 2012
The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. 1993David Vetrie, Igor Vořechovský, Paschalis Sideras, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
BMJ Open|August 23, 2023
Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessmentSally-Anne Dews, Adit Bassi, Sean Buckland, et al.
JMIR Formative Research|May 24, 2019
Digitizing a Face-to-Face Group Fatigue Management Program: Exploring the Views of People With Multiple Sclerosis and Health Care Professionals Via Consultation Groups and InterviewsSarah Thomas, Andy Pulman, Peter Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trialBarbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2004
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in CaliforniaCynthia L Martel, Yueju Li, Laurel Beckett, et al.
Pageof 7